Pharmacodynamic Study of dexmedetomidine sedation in children

Comparison of Median effective dose of dexmedetomidine in children with Congenital heart disease before and after surgery undergoing transthoracic echocardiography examination

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17012665

Enrollment

Unknown

Registered

2017-09-14

Start date

2017-09-19

Completion date

Unknown

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital cardiovascular disease

Interventions

1:intranasal dexmedetomidine1ug/Kg~4ug/Kg

2:dexmedetomidine1ug/Kg~4ug/Kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: children, 0 to 48 months old,with Congenital heart disease and to be classified as American Society of Anesthesiologists physical status I or II

Exclusion criteria

Exclusion criteria: 1. known allergy to dexmedetomidine; 2. recent treatment with a-2 adrenergic receptor agonist; 3. renal or hepatic dysfunction; 4. nasal discharges; 5. history of preterm birth.

Design outcomes

Primary

Measure	Time frame
heart rate;Oxygen saturation;respiration rate;	—

Countries

China

Contacts

Public ContactShengfen Tu

Children's Hospital of Chongqing Medical University

519194496@qq.com+86 13983416114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026